"Designing Growth Strategies is in our DNA"
In October 2018, IDIBELL-Bellvitge Biomedical Research Institute examined the safety and efficacy of a new molecule against chemotherapy-induced peripheral neuropathy. Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of many commonly used chemotherapeutic agents, which includes vinca alkaloids, platinum drugs, epothilones, taxanes, and also newer agents such as bortezomib and lenolidamide.
Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a painful dysfunction of the somatosensory nervous system. Chemotherapy-Induced Peripheral Neuropathy (CIPN) affects an estimated 68.0% of patients undergoing chemotherapy within the first month and affects 30% of patients on a chronic basis.
To gain extensive insights into the market, Request for Customization
Increasing adoption of chemotherapy is one of the prime factor for increasing prevalence of peripheral neuropathy. Moreover, lack of proper guidelines regarding chemotherapy elevates the chances of additional incidence of peripheral neuropathy. Such factors are expected to drive the growth of the chemotherapy induced peripheral neuropathy market during the forecast period.
Lack of awareness regarding symptoms of chemotherapy induced peripheral neuropathy is expected to hamper the growth of the chemotherapy induced peripheral neuropathy treatment market during the forecast period.
Some of the major companies that are present in the global chemotherapy induced peripheral neuropathy treatment market are Eurofins Advinus, WEX Phamaceuticals Inc., Asahi Kasei Corporation., MediciNova, Inc., Solasia Pharma K.K., ESTEVE, ChromaDex, Inc., Apollo Endosurgery, Inc., F. Hoffmann-La Roche Ltd., Midatech Pharma PLC, Novartis AG, Lee's Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA and other prominent players.
· Anti-Seizure Medicines
By Distribution Channel
· Hospital Pharmacy
· Retails Pharmacy
· Online Pharmacy
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Among the segmentation, steroids are projected to hold a considerable share of the global chemotherapy induced peripheral neuropathy treatment market owing greater efficacy and high adoption of the steroidal drugs across each geographical region.
On the basis of region, the global chemotherapy induced peripheral neuropathy treatment market is segmented as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among the region, North America is expected to dominate global chemotherapy induced peripheral neuropathy treatment market during the forecast period. Increasing prevalence of cancer is leading to rise in the demand for the chemotherapy treatment by the patients in the North America region. This is anticipated to drive the growth of the chemotherapy induced peripheral neuropathy treatment in North America. According to Centre for Disease Control and Prevention (CDC), in 2015, an estimated 1,633,390 new cases of cancer were reported, and an estimated 595,919 people died of cancer in the United States. Europe and Asia Pacific are anticipated to grow at a significant CAGR in the forecast period of 2019-2026.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry